PRECIPIO DIAGNOSTICS
Precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. Our goal is to assist oncologists in providing the best care for their patients. At the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the Yale School of Medicine. At Precipio, our customers and their patients benefit from the most accurate, expert diagnosis.
PRECIPIO DIAGNOSTICS
Industry:
Biotechnology Health Care Health Diagnostics Precision Medicine
Founded:
2011-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.precipiodx.com
Total Employee:
51+
Status:
Active
Contact:
(203)787-7888
Email Addresses:
[email protected]
Total Funding:
3.77 M USD
Technology used in webpage:
Domain Not Resolving Euro Mobile Non Scaleable Content Ruby On Rails Token Ninja Forms Yii Framework OneSignal
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Boutique Venture Partners
Boutique Venture Partners specializes in early stage investments in healthcare and life sciences.
Group K Diagnostics
We put patient health 1st by revolutionizing rapid blood testing with a hand-held chemistry and ID analyzer for everyone, all in one.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Liquid Biotech
Liquid Biotech is a technology for cancer diagnostics and gene discover
MedTech Innovator
MedTech Innovator is the largest lifescience accelerator in the world for medical device, digital health, and diagnostic companies
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-06-30 | Transgenomic | Transgenomic acquired by Precipio Diagnostics | N/A |
Investors List
Eli Whitney Fund
Eli Whitney Fund investment in Series B - Precipio Diagnostics
Kuzari Group
Kuzari Group investment in Series B - Precipio Diagnostics
Ironwood Capital
Ironwood Capital investment in Series B - Precipio Diagnostics
Enhanced Capital Partners
Enhanced Capital Partners investment in Series B - Precipio Diagnostics
Advantage Capital
Advantage Capital investment in Series B - Precipio Diagnostics
Connecticut Innovations
Connecticut Innovations investment in Series B - Precipio Diagnostics
Official Site Inspections
http://www.precipiodx.com Semrush global rank: 7.13 M Semrush visits lastest month: 883
- Host name: 172.66.43.84
- IP address: 172.66.43.84
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Precipio Diagnostics"
Precipio Diagnostics - Crunchbase Company Profile & Funding
Organization. Precipio Diagnostics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; …See details»
Hematopathology | Blood Cancer Testing | Molecular …
Advanced Hematopathology Diagnostics: Exceptional Accuracy and Testing Efficiency. Precipio creates proprietary hematopathology diagnostic products that help laboratories achieve faster and more efficient throughput, improve their …See details»
Empowering Care with Blood Cancer Diagnostics - Precipio
About Precipio. Precipio’s platform delivers superior diagnostic accuracy through academic expertise and cutting edge technology. We are a laboratory focused on delivering specialized …See details»
Precipio Announces Q3-2024 Shareholder Update Call
Nov 6, 2024 Conference Call to be held on November 18, 2024, at 5:00 PM EST. NEW HAVEN, CT, (November 6, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: …See details»
Working At Precipio: Company Overview and Culture - Zippia
May 18, 2020 precipiodx.com. Organization Type. Public. Social Media. Precipio, as translated from Latin, means "to advise", and "to anticipate". We see this as the heart of our company's …See details»
Precipio Announces Q3-2024 Shareholder Update Call - Yahoo …
Nov 6, 2024 Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company …See details»
Precipio, Inc. Announces Pricing of $2 Million Registered Direct ...
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities …See details»
Precipio, Inc. (PRPO) Stock Price, Quote & News - Stock Analysis
6 days ago Website https://www.precipiodx.com. Full Company Profile. Financial Performance. In 2023, Precipio's revenue was $15.20 million, an increase of 61.46% compared to the …See details»
Precipio Announces Christina Valauri joins the Board of
NEW HAVEN, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is pleased to welcome Christina Valauri to its board …See details»
Investors - Precipio
For Investors: Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertiseSee details»
Precipio Announces Q3-2024 Shareholder Update Call
Jun 11, 2024 Conference Call to be held on November 18, 2024, at 5:00 PM EST. NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics …See details»
PRECIDX
Precidx, a healthcare data optimization company, was founded in 2020 by a team of innovators who envisioned a future where enterprise imaging could be fully leveraged to power precision …See details»
Precipio Announces Q3-2024 Shareholder Update Call
Nov 6, 2024 Conference Call to be held on November 18, 2024, at 5:00 PM EST. NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company …See details»
Precipio Ships First IV-Cell® Order to Major US Healthcare System
Mar 21, 2023 Products Division revenues begin to diversify beyond HemeScreen® NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics …See details»
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap …
Jul 17, 2024 Pathology Revenues in June exceed breakeven target and continue growth trendNEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer …See details»
Precipio Announces Q3-2024 Shareholder Update Call
Nov 6, 2024 The call will discuss the company's Q3-2024 10-Q filing and provide financial highlights and analysis of core businesses. Shareholders can access the call via phone (844 …See details»
Our Culture - Precipio
Precipio’s culture is one of care, and putting the patient first. The company exists to battle the problem of misdiagnosis; A problem that affects hundreds of thousands of patients, and their …See details»
Precipio Announces a Shareholder Call to Discuss its COVID-19 …
Sep 4, 2020 Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategyNEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- …See details»
Precipio Announces 2022 Fourth Quarter and Year-End …
Mar 28, 2023 Conference Call to be held on Monday, April 3 rd, 2023 at 5:00 PM EST. NEW HAVEN, CT, Globenewswire – (March 28 th, 2023) – Specialty cancer diagnostics company …See details»
Biotech News | Press Releases - Precipio
Jul 25, 2024 Learn more about Biotech News and press releases from Precipio. Stay updated on all news and information related to the industry.See details»